Sunmax Biotechnology (4728) Stock Overview

Sunmax Biotechnology Co., Ltd., a biomedical company, develops, manufactures, and markets medical-grade collagen-based medical devices in Asia. The company offers Porcogen, a sterile purified collagen solution for medical device, tissue engineering, and research purposes; and dermal fillers, such as Sunmax collagen implant I-Plus and Sumax collagen implant I for the correction of facial defects, such as the fill up of wrinkles. It also provides Sunmax collagen dental bone graft, Sunmax collagen dental membrane, and Sunmax dental bone graft granules, which are used in the augmentation or reconstructive treatment of the alveolar ridge. In addition, the company offers Sunmax collagen bone graft matrix that provides a bone void filler that is resorbed and replaced with bone during the healing process; and skincare products comprising Sunmax 6 collagen facial cleanser, Sunmax 7 collagen essence, Sunmax 8 active collagen essence mask, Sunmax 9 collagen refining cream, Sunmax 10 collagen eye renewal cream, Sunmax 11 collagen moisturizing cream, Sunmax 15 Collagen MesoRepair, and Sunmax Collagen Peptide that are used as aftercare of dermal filler treatment. Sunmax Biotechnology Co., Ltd. was founded in 2001 and is based in Tainan City, Taiwan.